Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs
Robert S. Kerbel
Cancer Res Treat. 2007;39(4):150-159.   Published online 2007 Dec 31     DOI: https://doi.org/10.4143/crt.2007.39.4.150
Citations to this article as recorded by Crossref logo
Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
Piotr J. Wysocki, Mateusz Łobacz, Paweł Potocki, Łukasz Kwinta, Anna Michałowska-Kaczmarczyk, Agnieszka Słowik, Kamil Konopka, Anna Buda-Nowak
Cancers.2023; 15(4): 1067.     CrossRef
Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature
Benjamin Carcamo, Giulio Francia
Journal of Clinical Medicine.2022; 11(10): 2849.     CrossRef
Muscarinic Receptors Associated with Cancer
Gloria M. Calaf, Leodan A. Crispin, Juan P. Muñoz, Francisco Aguayo, Tammy C. Bleak
Cancers.2022; 14(9): 2322.     CrossRef
De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?
Palma Fedele, Valeria Sanna, Alessandro Fancellu, Antonella Marino, Nicola Calvani, Saverio Cinieri
Critical Reviews in Oncology/Hematology.2021; 157: 103148.     CrossRef
Metronomics in Pediatric Oncology: Lessons Learned and the Way Forward
Raja Pramanik, Sameer Bakhshi
Indian Journal of Medical and Paediatric Oncology.2020; 41(03): 317.     CrossRef
Optimal Impulsive Control With Application to Antiangiogenic Tumor Therapy
Filippo Cacace, Valerio Cusimano, Pasquale Palumbo
IEEE Transactions on Control Systems Technology.2020; 28(1): 106.     CrossRef
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma
Shengnan Zhao, Yakun Zhang, Lei Wang, Li Yang, Liqun Zou, Fabao Gao
Cancer Biology & Therapy.2019; 20(1): 65.     CrossRef
Tumor endothelial cells as a potential target of metronomic chemotherapy
Ji Yoon Kim, Young-Myeong Kim
Archives of Pharmacal Research.2019; 42(1): 1.     CrossRef
Analyses of the Temperature Field of a Piezoelectric Micro Actuator in the Endoscopic Biopsy Channel
Zhu, Peng, Yang
Applied Sciences.2019; 9(21): 4499.     CrossRef
The use of low‐dose metronomic chemotherapy in dogs—insight into a modern cancer field
T. B. Gaspar, J. Henriques, L. Marconato, F. L. Queiroga
Veterinary and Comparative Oncology.2018; 16(1): 2.     CrossRef
Dental pulp stem cells used to deliver the anticancer drug paclitaxel
Hamideh Salehi, Siham Al-Arag, Elodie Middendorp, Csilla Gergely, Frederic Cuisinier, Valerie Orti
Stem Cell Research & Therapy.2018;[Epub]     CrossRef
Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis
William H. Isacoff, Howard A. Reber, Rudolph Bedford, William Hoos, Lola Rahib, Alexander Upfill-Brown, Timothy Donahue, O. Joe Hines
Targeted Oncology.2018; 13(4): 461.     CrossRef
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
John P. Fruehauf, Monica El-Masry, Katherine Osann, Basmina Parmakhtiar, Maki Yamamoto, James G. Jakowatz
Cancer Chemotherapy and Pharmacology.2018; 82(2): 353.     CrossRef
Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer
Koji Harada, Tarannum Ferdous, Yoshiya Ueyama
Japanese Dental Science Review.2017; 53(3): 61.     CrossRef
Optimal discrete time control of antiangiogenic tumor therapy * *This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 679681). D.A. Drexler
Dániel András Drexler, Johanna Sápi, Levente Kovács
IFAC-PapersOnLine.2017; 50(1): 13504.     CrossRef
Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity
Serena Mazzucchelli, Michela Bellini, Luisa Fiandra, Marta Truffi, Maria A. Rizzuto, Luca Sorrentino, Erika Longhi, Manuela Nebuloni, Davide Prosperi, Fabio Corsi
Oncotarget.2017; 8(5): 8383.     CrossRef
Penetration and Silencing Activity of VEGF Dicer Substrate siRNA Vectorized by Chitosan Nanoparticles in Monolayer Culture and a Solid Tumor ModelIn Vitrofor Potential Application in Tumor Therapy
Maria Abdul Ghafoor Raja, Haliza Katas, Zariyantey Abd Hamid
Journal of Nanomaterials.2016; 2016: 1.     CrossRef
Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer
Roberto Petrioli, Giandomenico Roviello, Anna Ida Fiaschi, Letizia Laera, Salvatora Tindara Miano, Daniele Marrelli, Franco Roviello, Vincenzo Bianco, Edoardo Francini
Future Oncology.2015; 11(18): 2563.     CrossRef
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
Teresa Di Desidero, Ping Xu, Shan Man, Guido Bocci, Robert S. Kerbel
Oncotarget.2015; 6(40): 42396.     CrossRef
Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer
Ho-Suap Hahn, Ki-Heon Lee, In-Ho Lee, Jae-Ho Lee, Chang-Sung Whang, Yeong-Woo Jo, Tae-Jin Kim
Journal of Gynecologic Oncology.2014; 25(2): 130.     CrossRef
Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
Gabriella Ferrandina, Giacomo Corrado, Floriana Mascilini, Paola Malaguti, Riccardo Samaritani, Mariagrazia Distefano, Valeria Masciullo, Alessia Di Legge, Antonella Savarese, Giovanni Scambia
BMC Cancer.2014;[Epub]     CrossRef
Weekly Administration of Bevacizumab, Gemcitabine, and Oxaliplatin in Patients With Recurrent and Refractory Ovarian Cancer
Yuji Ikeda, Masashi Takano, Katsutoshi Oda, Hiroko Kouta, Tomoko Goto, Kazuya Kudoh, Naoki Sasaki, Tsunekazu Kita, Yoshihiro Kikuchi
International Journal of Gynecological Cancer.2013; 23(2): 355.     CrossRef
Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells
TARANNUM FERDOUS, KOJI HARADA, TAKANORI KIN, TOYOKO HARADA, YOSHIYA UEYAMA
International Journal of Oncology.2013; 43(1): 271.     CrossRef
Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
Yoshinori Ito, Takuji Iwase, Kiyohiko Hatake
Breast Cancer.2012; 19(3): 206.     CrossRef
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study
Veronica Marchetti, Mario Giorgi, Anna Fioravanti, Riccardo Finotello, Simonetta Citi, Bastianina Canu, Paola Orlandi, Teresa Di Desidero, Romano Danesi, Guido Bocci
Investigational New Drugs.2012; 30(4): 1725.     CrossRef
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy
Manuela Miscoria, Fabrizio Tonetto, Laura Deroma, Piernicola Machin, Carla Di Loreto, Pamela Driol, Alessandro Marco Minisini, Stefania Russo, Claudia Andreetta, Mauro Mansutti, Giuseppe Damante, Gianpiero Fasola, Fabio Puglisi
Anti-Cancer Drugs.2012; 23(3): 326.     CrossRef
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
Uzma Asghar, Tim Meyer
Journal of Hepatology.2012; 56(3): 686.     CrossRef
Metronomic therapy for gynecologic cancers
Wen-Hsiang Su, Tien-Yu Ho, Yiu-Tai Li, Chien-Hsing Lu, Wen-Ling Lee, Peng-Hui Wang
Taiwanese Journal of Obstetrics and Gynecology.2012; 51(2): 167.     CrossRef
Controlling escape from angiogenesis inhibitors
Barbara Sennino, Donald M. McDonald
Nature Reviews Cancer.2012; 12(10): 699.     CrossRef
Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer
Ursula A. Matulonis, Lauren Pereira, Joyce Liu, Hang Lee, Julie Lee, Christin Whalen, Susana Campos, Tina Atkinson, Margaret Hill, Suzanne Berlin
Gynecologic Oncology.2012; 126(1): 41.     CrossRef
Tumor angiogenesis: molecular pathways and therapeutic targets
Sara M Weis, David A Cheresh
Nature Medicine.2011; 17(11): 1359.     CrossRef
Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma
Jeong Won Jang, Seong Tae Park, Jung Hyun Kwon, Chan Ran You, Jong Young Choi, Chan-Kwon Jung, Si Hyun Bae, Seung Kew Yoon
Experimental and Molecular Medicine.2011; 43(5): 305.     CrossRef
Off-tumor target—beneficial site for antiangiogenic cancer therapy?
Yihai Cao
Nature Reviews Clinical Oncology.2010; 7(10): 604.     CrossRef
Optimizing the Delivery of Cancer Drugs That Block Angiogenesis
Yihai Cao, Robert Langer
Science Translational Medicine.2010;[Epub]     CrossRef
New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future
Melissa Taylor, Jochen Rössler, Birgit Geoerger, Gilles Vassal, Françoise Farace
Expert Opinion on Investigational Drugs.2010; 19(7): 859.     CrossRef
Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer
Hop S. Tran Cao, Michael Bouvet, Sharmeela Kaushal, Alex Keleman, Eric Romney, Ginna Kim, John Fruehauf, David K. Imagawa, Robert M. Hoffman, Matthew H.G. Katz
Molecular Cancer Therapeutics.2010; 9(7): 2068.     CrossRef
Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro
Ahmed M. Al-Abd, Soo Hyeon Lee, Sun Hwa Kim, Jung-Ho Cha, Tae Gwan Park, Seung Jin Lee, Hyo-Jeong Kuh
Journal of Controlled Release.2009; 137(2): 130.     CrossRef